Over the last 7 days, the United States market has dropped 4.8%, yet it has risen by 15% over the past year, with earnings anticipated to grow by 14% annually in the coming years. In this context, identifying high growth tech stocks involves looking for companies that demonstrate strong potential through innovation and adaptability to leverage these market dynamics effectively.

Top 10 High Growth Tech Companies In The United States

Click here to see the full list of 225 stocks from our US High Growth Tech and AI Stocks screener.

Underneath we present a selection of stocks filtered out by our screen.

Amicus Therapeutics

Simply Wall St Growth Rating: ★★★★★☆

Overview: Amicus Therapeutics, Inc. is a biotechnology company dedicated to the discovery, development, and delivery of medicines for rare diseases with a market cap of approximately $2.71 billion.

Operations: The company's primary revenue stream, totaling $528.30 million, is derived from the discovery, development, and commercialization of advanced therapies for rare diseases.

Amicus Therapeutics, despite its unprofitability, is on a promising trajectory with expected revenue growth of 17.5% annually, outpacing the US market average of 8.7%. The company's recent reduction in net loss from $151.58 million to $56.11 million year-over-year highlights significant financial improvement and operational efficiency. Looking ahead, Amicus anticipates positive GAAP Net Income in the latter half of 2025 and projects revenue increases between 17% to 24%. This forward-looking optimism is supported by robust R&D investments aimed at pioneering treatments in biotechnology, positioning it well within the high-growth tech landscape despite current financial challenges.

• Unlock comprehensive insights into our analysis of Amicus Therapeutics stock in this health report.

• Assess Amicus Therapeutics' past performance with our detailed historical performance reports.

Vanda Pharmaceuticals

Simply Wall St Growth Rating: ★★★★★☆

Overview: Vanda Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing therapies for high unmet medical needs globally, with a market cap of $274.67 million.

Operations: Vanda Pharmaceuticals focuses on developing and commercializing biopharmaceutical therapies, generating revenue primarily from its biotechnology segment with $198.77 million.

Vanda Pharmaceuticals, amidst a challenging regulatory landscape, continues to innovate in the treatment of rare diseases. The company’s recent development of VCA-894A, an antisense oligonucleotide for Charcot-Marie-Tooth disease type 2S, underscores its commitment to precision medicine—a field gaining traction within high-growth tech sectors. Despite reporting a widening net loss in Q4 2024 to $4.91 million from $2.4 million the previous year, Vanda projects significant future revenue growth; it anticipates exceeding $1 billion by 2030 with potential approvals on the horizon for Bysanti™ across multiple indications. This forward-looking strategy highlights its pivot towards addressing unmet medical needs through targeted therapies and could reshape treatment paradigms in neuropsychiatric and neurological disorders.

• Delve into the full analysis health report here for a deeper understanding of Vanda Pharmaceuticals.

• Learn about Vanda Pharmaceuticals' historical performance.

Kiniksa Pharmaceuticals International

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Kiniksa Pharmaceuticals International, plc is a biopharmaceutical company dedicated to discovering, acquiring, developing, and commercializing therapeutic medicines for patients with debilitating diseases that have significant unmet medical needs globally, with a market cap of approximately $1.43 billion.

Operations: Kiniksa Pharmaceuticals generates revenue primarily from developing and delivering therapeutic medicines, totaling $423.24 million. The company focuses on addressing significant unmet medical needs in debilitating diseases worldwide.

Kiniksa Pharmaceuticals International, despite a challenging year with a net loss of $43.19 million, is positioning itself for recovery and growth with strategic product developments. In 2024, the company's revenue surged to $423.24 million from $270.26 million the previous year, marking a significant 56% increase. This growth trajectory is supported by innovations such as KPL-387 for recurrent pericarditis and an expected profitable turn within three years. With annual earnings projected to grow by 46.45%, Kiniksa continues to prioritize unmet medical needs in cardiovascular indications, potentially reshaping treatment paradigms and enhancing its market position in high-growth biotech sectors.

• Dive into the specifics of Kiniksa Pharmaceuticals International here with our thorough health report.

• Evaluate Kiniksa Pharmaceuticals International's historical performance by accessing our past performance report.

Key Takeaways

• Take a closer look at our US High Growth Tech and AI Stocks list of 225 companies by clicking here.
• Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools.
• Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage.

Curious About Other Options?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NasdaqGM:FOLD NasdaqGM:VNDA and NasdaqGS:KNSA.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com